Sitemap > News > Cancer Immunotherapy
- Data Show Improved Response Rate when Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
- CytImmune Presents Positive CYT-6091 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
- Introgen Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
- Oxford BioMedica and Sanofi-Aventis Report Encouraging New Trovax® Phase II Trial Results in Renal Cancer
- Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
- Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
- Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
- OXFORD BIOMEDICA AND SANOFI-AVENTIS REPORT NEW TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER
- Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
- Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
- ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
- Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
- Antigenics’ QS-21 Stimulon Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline’s Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
- Biovest to File for Accelerated Conditional Approval of BiovaxID
- Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
- Encouraging clinical activity of GSK’s novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
- IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS WITH hPAM4 FOR PANCREATIC CANCER THERAPY
- Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
- YM BIOSCIENCES CLEARED TO INITIATE CLINICAL TRIAL OF NIMOTUZUMAB IN COLORECTAL CANCER
- FDA Accepts and Grants Priority Review of Erbitux (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
- CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine
- Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted
- GENMAB ANNOUNCES DEVELOPMENT PLANS FOR OFATUMUMAB
- Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
- MorphoSys Announces Clinical Milestone in Partnered Therapeutic Antibody Program - Third HuCAL-based Antibody to Begin Clinical Trials
- Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer
- Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
- Oncolytics Biotech Inc. Commences Patient Enrolment in U.S. Phase II Sarcoma Clinical Trial
- Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
- VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- California Biotechnology Company Takes Aim At Pancreatic Cancer With An Advanced Phase I/Ii Clinical Trial Using Rexin-G, A Targeted Injectable Gene Delivery System
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- GERON INITIATES CLINICAL TRIAL OF TELOMERASE CANCER VACCINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
- Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
- Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient Enrollment
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer
- Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
- ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
- YM BIOSCIENCES INITIATES PATIENT ENROLMENT IN PHASE II COLORECTAL CANCER TRIAL WITH EGFR ANTIBODY
- Antigenics Provides Update on Filing for Approval of Oncophage in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Enzon Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for Advanced Solid Tumors and Lymphoma
- Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
- Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
- GammaCan Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma
- Phase II Study of IMC-11F8 for Advanced Colorectal Cancer Has Commenced Patient Enrollment in Europe
- Kiadis Pharma Completes Patient Enrollment of Rhitol phase I/II Clinical Trial
- YM BIOSCIENCES’, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
- Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
- IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
- Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment
- lmmutep Announces That ImmuFacf IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in Melanoma
- Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
- YM BIOSCIENCES USA CLEARED BY US FDA TO INITIATE PHASE II CLINICAL TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER
- Merck Applies to Extend Use of Erbitux® for 1st-Line Colorectal Cancer
- Oral Cancer Drug REVLIMID® Receives Swissmedic Approval in Switzerland For Treatment of Multiple Myeloma
- Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients
- YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
- Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
- Introgen\'s p53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin
- ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
- Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
- Xeloda® XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
- Genmab Discloses Target and Development Plans for HuMax-Inflam
- DAHANCA Initiates Head and Neck Cancer Study with Genmab’s HuMax-EGFr
- Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
- Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study
- European Committee Issues Positive Opinion on Wyeth\'s TORISEL for Advanced Renal Cell Carcinoma
- Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
- ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
- Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
- Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer - one of the most aggressive and fastest growing forms of the disease
- GENMAB AMENDS OFATUMUMAB PIVOTAL STUDY IN NHL TO SINGLE ARM STUDY
- Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial
- Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer
- Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer Study Released
- Biothera initiates Phase Ib/IIa clinical trial in cancer patients
- First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage Cancer Vaccine in Glioma
- GENMAB AMENDS HUMAX-CD4 PIVOTAL STUDY IN CTCL
- VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta™
- Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID
- Aperio Receives FDA Approval for HER2 Image Analysis Application
- Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
- Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal™ as a First Line Treatment for Acute Graft vs. Host Disease
- U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
- Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
- Nventa Updates Progress of Cervical Dysplasia Trial with New HSPE7
- Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- MabCampath Receives Positive Opinion from European Committee for Medicinal Products for Human Use
- Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge® For Advanced Prostate Cancer
- ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
- NCCN Updates Central Nervous System Cancers Guidelines
- NCCN Updates Multiple Myeloma Guidelines
- NCCN Updates Non-Small Cell Lung Cancer Guidelines
- Phase I Results Announced for R1507 from Genmab’s Collaboration with Roche
- Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial
- ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar
- CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
- IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
- IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
- Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
- Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma
- FDA grants Kiadis Pharma lead product ATIR orphan drug designation
- BioGeneriX and Neose Technologies Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
- Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
- Athersys IND for MultiStem Authorized for Phase I Clinical Trial in Bone Marrow Transplant Support.
- Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
- Introgen\'s ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
- Nventa Updates Progress With New HSPE7 In Phase 1 Trial In Cervical Dysplasia
- Genmab Announces Update on Recruitment of Patients in Ofatumumab CLL Pivotal Study
- ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
- Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine♦ (VNP40101M) in Combination with Stem Cell Transplantation
- Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
- Genentech Provides Update From Avastin FDA Advisory Meeting
- Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin\'s Lymphoma
- HEMISPHERX BIOPHARMA RECEIVES NOTICE OF INCOMPLETE NEW DRUG APPLICATION (NDA)
- ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma
- EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
- GENMAB’S HUMAX-CD38 ENTERS PHASE I/II CLINICAL TRIAL FOR MULTIPLE MYELOMA
- Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin\'s Lymphoma
- Chemokine Therapeutics Continues patient Therapy using CTCE-9908 and Extends Closing of its Phase I/II Clinical Trial
- Phase II Study of IMC-1121B for Advanced Malignant Melanoma Commences Patient Enrollment
- December 12, 2007. GERON RECEIVES MILESTONE PAYMENT FROM MERCK TRIGGERED BY IND FILING FOR TELOMERASE CANCER VACCINE CANDIDATE
- GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine
- ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma
- Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer
- Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
- Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination with Chemotherapy
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
- Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of MyVax(R) Personalized Immunotherapy
- R1507 Antibody to Enter Phase II Study to Treat Sarcoma
- GenVec Announces Protocol Changes for PACT Study After Discussions with FDA
- Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN
- Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax®-L at University of Pennsylvania
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined with Nexavar(R)
- Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
- Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
- Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
- TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody
- Transgene\'s therapeutic vaccine TG4010 shows promising preliminary phase IIb
- Interim Analysis Supports Continuation of Cell Genesys\' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- NVENTA Completes Evaluation Of Second Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- ThromboGenics and BioInvent receive approval to begin clinical trials of TB-403 for the treatment of cancer
- Apthera Files a Phase III Special Protocol Assessment with FDA for NeuVax in Early-Stage Breast Cancer Patients
- Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
- NVENTA Concludes Enrollment And Initial Dosing Of Third Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- ImmunoVaccine Technologies Discusses Phase I Clinical Trial Application
- Celprogen Launches Caner Stem Cells
- Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
- MolMed gets approval to start Phase III of TK in high risk acute leukaemia
- EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
- Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
- Kiadis Pharma announces successful completion of Rhitol Phase II clinical study
- FDA Grants Priority Review for Schering-Plough\'s Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
- FDA Gives Green Light to Lpath\'s ASONEP IND Submittal
- Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
- Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma
- Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint
- YM BIOSCIENCES USA ENROLLS FIRST PATIENT IN PHASE II TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER
- Introgen\'s p53 Immunotherapy INGN 225 Begins Randomized, Controlled Clinical Trial in Patients with Small Cell Lung Cancer
- Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications
- Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
- Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
- Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
- Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax Phase III TRIST Study
- FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
- Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
- Bradmer Announces Phase II Results Published In Newly Diagnosed Glioblastoma Which Demonstrate Improved Survival And Support Upcoming Phase III Study
- Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
- Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy
- NVENTA Evaluation Complete For First Three Cohorts In HSPE7 Phase 1 Cervical Dysplasia Trial
- InvestBio Portfolio Company Presents Phase I/II Trial Results of Vaccine for Leukemia at American Society of Hematology Annual Meeting
- Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
- Ichor Melanoma Vaccine Clinical Trial Moves to the Highest Dose Level
- NVENTA Enrolls And Initiates Dosing Of Final Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- Genitope Corporation to Suspend Development of MyVax(R) Personalized Immunotherapy
- FDA Agrees to Amend Dendreon\'s Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
- RAVEN BIOTECHNOLOGIES ADVANCES RAV 18 THROUGH AGREEMENT WITH CMC ICOS BIOLOGICS
- Printer Friendly Version Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin\'s Lymphoma
- GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer at Memorial Sloan Kettering
- Supplemental Application for GARDASIL®, Merck\'s Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
- OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy
- Oxford BioMedica Report Encouraging New Phase II Trial Results with TroVax® in Prostate Cancer
- Nventa Announces Positive Interim Immunological Data From HSPE7 Phase 1 Cervical Dysplasia Trial
- Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
- FAST Clinical Trial FDA Approved
- Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
- Medarex Announces Ipilimumab Program Continues to Move Forward
- Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
- Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment
- CuraGen Advances CR011-vcMMAE into Phase II
- Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
- Genitope Corporation\'s MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial Results Available on Company Website
- Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease
- New Phase III Data Confirm Phase II Findings of ADVEXIN(R) Efficacy
- Significant Tumor-Specific Immune Response Observed in AVANT\'s Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme
- Cell Genesys Reports Data on an Association Between Immune Response and Anti-Tumor Activity in Patients Receiving GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010)
- Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
- Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID
- Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals
- ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
- Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
- HUMAN GENOME SCIENCES COMPLETES ENROLLMENT IN FIRST OF TWO PHASE 3 LYMPHOSTAT-B TRIALS
- FDA agrees to first SPA for an oncolytic product
- Nventa Completes Safety Evaluation On Final Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
- Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
- Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells
- MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
- Osiris Receives Approval for Use of Prochymal Under FDA Expanded Access Treatment Program
- Nventa Announces Additional Positive Immunological Data From HSPE7 Phase 1 Cervical Dysplasia Trial
- NOVELOS THERAPEUTICS ANNOUNCES POSITIVE RESULTS IN ONGOING PHASE 2 NEOADJUVANT BREAST CANCER TRIAL AT MUSC HOLLINGS CANCER CENTER
- Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
- Active Biotech advances ANYARA into Phase III clinical trial
- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin
